Skip to content

Correlation between blood mRNA expression levels and disease severity in patients with Parkinson's disease and Alzheimer's disease

Correlation between blood mRNA expression levels and disease severity in patients with Parkinson's disease and Alzheimer's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076996
Enrollment
Unknown
Registered
2023-10-26
Start date
2023-10-28
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Case group:NA
Control group:NA
Healthy control group:NA

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The 100 patients with Parkinson's disease (PD) who met the diagnostic criteria and exclusion criteria were 100 patients aged 45-80 in the neurology ward/outpatient department of the First Affiliated Hospital of Chongqing Medical University; (2) 100 AD patients aged 55-80 years were collected as a control group in outpatient clinics; (3) 100 healthy people were collected by recruitment, who did not suffer from neurological diseases but matched with the case group in gender, age, and past medical history. The diagnosis of patients with Parkinson's disease is based on the British Parkinson's Society Brain Bank Clinical Diagnostic Criteria. AD is diagnosed using the International Diagnostic Standards for Senile Dementia adopted by the Tenth Revision of 1992 (ICD-10).

Exclusion criteria

Exclusion criteria: (1) Patients suffering from other central nervous system diseases, including cerebrovascular diseases, intracranial infections, other central nervous system autoimmune diseases, demyelinating diseases, trauma, tumors, toxic diseases and metabolic diseases; (2) Patients with confounding factors that affect the immune system, such as depression, chronic inflammatory diseases, coagulation abnormalities, history of malignant tumors, patients taking anticoagulant drugs and patients taking nonsteroidal anti-inflammatory drugs one week before enrollment; (3) Consciousness impairment, severe hearing impairment, severe cognitive dysfunction, dementia, etc. who cannot complete the relevant scale assessment; (4) Those who refuse to participate in this study.

Design outcomes

Primary

MeasureTime frame
DEGs;GO,KEGG;WGCNA;score of MDS-UPDRS;

Secondary

MeasureTime frame
score of the MMSE;score of RBD-SQ;score of SCOPA-AUT;score of PDSS;

Countries

China

Contacts

Public ContactOumei Cheng

The first affilaited hospital of chongqing medical university

chengoumei01@aliyun.com+86 131 0237 2730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026